Today's digital signage is much more than menus and campus-wide messaging. It is everything from a digital canvas for art to ...
Boehringer Ingelheim has reported encouraging Phase II trial results for apecotrep (BI 764198), a potential first-in-class oral TRPC6 inhibitor being developed for primary focal segmental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results